BlackRock’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-108,591
| Closed | -$71.7K | – | 5379 |
|
|
2024
Q2 | $71.7K | Hold |
108,591
| – | – | ﹤0.01% | 4782 |
|
|
2024
Q1 | $65.4K | Sell |
108,591
-3,369
| -3% | -$2.06K | ﹤0.01% | 4821 |
|
|
2023
Q4 | $65.8K | Hold |
111,960
| – | – | ﹤0.01% | 4909 |
|
|
2023
Q3 | $74.6K | Sell |
111,960
-185
| -0.2% | -$227 | ﹤0.01% | 4916 |
|
|
2023
Q2 | $369K | Sell |
112,145
-313,891
| -74% | -$949K | ﹤0.01% | 4572 |
|
|
2023
Q1 | $3.87M | Sell |
426,036
-19,290
| -4% | -$273K | ﹤0.01% | 3745 |
|
|
2022
Q4 | $5.23M | Sell |
445,326
-3,222
| -0.7% | -$56.8K | ﹤0.01% | 3701 |
|
|
2022
Q3 | $9.5M | Sell |
448,548
-8,375
| -2% | -$226K | ﹤0.01% | 3458 |
|
|
2022
Q2 | $11.1M | Buy |
456,923
+16,219
| +4% | +$552K | ﹤0.01% | 3452 |
|
|
2022
Q1 | $21.9M | Sell |
440,704
-1,603
| -0.4% | -$79.2K | ﹤0.01% | 3112 |
|
|
2021
Q4 | $31M | Buy |
442,307
+15,426
| +4% | +$1.3M | ﹤0.01% | 2998 |
|
|
2021
Q3 | $39.8M | Sell |
426,881
-2,542
| -0.6% | -$242K | ﹤0.01% | 2808 |
|
|
2021
Q2 | $43.2M | Sell |
429,423
-32,493
| -7% | -$3.17M | ﹤0.01% | 2798 |
|
|
2021
Q1 | $43.1M | Buy |
461,916
+22,718
| +5% | +$2.3M | ﹤0.01% | 2714 |
|
|
2020
Q4 | $36.2M | Buy |
439,198
+31,629
| +8% | +$2.7M | ﹤0.01% | 2677 |
|
|
2020
Q3 | $35M | Sell |
407,569
-28,317
| -6% | -$3.3M | ﹤0.01% | 2506 |
|
|
2020
Q2 | $40.5M | Buy |
435,886
+46,591
| +12% | +$2.57M | ﹤0.01% | 2383 |
|
|
2020
Q1 | $11.1M | Buy |
389,295
+44,717
| +13% | +$1.74M | ﹤0.01% | 2936 |
|
|
2019
Q4 | $14.3M | Buy |
344,578
+197,812
| +135% | +$4.33M | ﹤0.01% | 3068 |
|
|
2019
Q3 | $2.07M | Buy |
146,766
+5,956
| +4% | +$125K | ﹤0.01% | 3744 |
|
|
2019
Q2 | $4.94M | Buy |
140,810
+134,378
| +2,089% | +$7.29M | ﹤0.01% | 3533 |
|
|
2019
Q1 | $361K | Buy |
+6,432
| New | +$348K | ﹤0.01% | 4147 |
|
|
2018
Q2 | – | Sell |
-50,530
| Closed | -$5.31M | – | 5104 |
|
|
2018
Q1 | $5.31M | Buy |
50,530
+220
| +0.4% | +$26.3K | ﹤0.01% | 3406 |
|
|
2017
Q4 | $6.45M | Buy |
50,310
+19,568
| +64% | +$2.41M | ﹤0.01% | 3349 |
|
|
2017
Q3 | $3.55M | Buy |
30,742
+871
| +3% | +$105K | ﹤0.01% | 3566 |
|
|
2017
Q2 | $3.9M | Buy |
29,871
+27,898
| +1,414% | +$3.76M | ﹤0.01% | 3537 |
|
|
2017
Q1 | $325K | Buy |
+1,973
| New | +$267K | ﹤0.01% | 4086 |
|
BlackRock's VBIV Position: Q3 2024 in Review
BlackRock sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 108,591 shares — an estimated $71.7K sold.
BlackRock first reported a position in VBIV in Q1 2017 and held it in 27 quarters. The position peaked at $43.2M in Q2 2021. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.
- BlackRock reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
- BlackRock sold 108,591 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $71.7K.
- BlackRock first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and held it in 27 quarters.
- BlackRock's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $43.2M in Q2 2021.
- 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.
Based on BlackRock's 13F filing for Q3 2024, filed 13 Nov 2024.